Prevalence of childhood overweight and obesity in rural Pune

Background: Urbanization and mechanization of lifestyle is leading to increase in childhood overweight and obesity in developing countries. Urban Indian studies report a prevalence of 5.5-24% of childhood obesity. The studies representing childhood obesity in rural areas, specifically, rural Pune are lacking. Objective: To determine the prevalence of overweight and obesity in children 10-15 years in rural Pune. Methods: Sociodemographic and anthropometric data were recorded of students from standards V to IX from a rural Pune school. Most recent and revised Indian Academy of Paediatrics (2015) body mass index criteria were applied. Results: Out of 449 children, 239 (53.2%) were boys and 210 (46.7%) were girls (mean age 12.8±1.3 years). The prevalence of overweight was 7.1% (12.5% boys and 8.5% girls) and of obesity was 3.6% (5% in boys and 1.9% in girls). Both overweight and obesity were more prevalent in boys as compared to girls. The proportion of overweight and obese children increased with higher parental educational status, being statistically significant in the case of mother’s educational status (p<0.005). Conclusion: Rural childhood overweight and obesity certainly warrant attention. Strategies for curtailing adult obesity should begin with the prevention and management of childhood obesity

A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections

Background: Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality.Methods: In this phase 3b/4 parallel, randomized, open-label, comparative study, 531 subjects with cSSSI received tigecycline (100 mg initial dose, then 50 mg intravenously every 12 hrs) or ampicillin-sulbactam 1.5-3 g IV every 6 hrs or amoxicillin-clavulanate 1.2 g IV every 6-8 hrs. Vancomycin could be added at the discretion of the investigator to the comparator arm if methicillin-resistant Staphylococcus aureus (MRSA) was confirmed or suspected within 72 hrs of enrollment. The primary endpoint was clinical response in the clinically evaluable (CE) population at the test-of-cure (TOC) visit. Microbiologic response and safety were also assessed. The modified intent-to-treat (mITT) population comprised 531 subjects (tigecycline, n = 268; comparator, n = 263) and 405 were clinically evaluable (tigecycline, n = 209; comparator, n = 196).Results: In the CE population, 162/209 (77.5%) tigecycline-treated subjects and 152/196 (77.6%) comparator-treated subjects were clinically cured (difference 0.0; 95% confidence interval [CI]: -8.7, 8.6). The eradication rates at the subject level for the microbiologically evaluable (ME) population were 79.2% in the tigecycline treatment group and 76.8% in the comparator treatment group (difference 2.4; 95% CI: -9.6, 14.4) at the TOC assessment. Nausea, vomiting, and diarrhea rates were higher in the tigecycline group.Conclusions: Tigecycline was generally safe and effective in the treatment of cSSSIs.Trial registration: ClinicalTrials.gov NCT00368537. © 2012 Matthews et al.; licensee BioMed Central Ltd